Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut J Ehrlich

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Seminars in Thrombosis and Hemostasis|July 16, 2010
Preclinical testing of human recombinant von Willebrand factor: ADAMTS13 cleavage capacity in animals as criterion for species suitabilityEva-Maria Muchitsch, Barbara Dietrich, Hanspeter Rottensteiner, et al.
Antimicrobial Agents and Chemotherapy|November 2, 2016
Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male SubjectsDidier Scherrer, Regine Rouzier, Marine Cardona, et al.
The Journal of Allergy and Clinical Immunology. Global|October 2, 2023
ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trialPedro Giavina-Bianchi, Eric Cua, Karine Risso, et al.
Vaccine|May 11, 2010
Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccineEva Maria Pöllabauer, Sandor Fritsch, Borislava G Pavlova, et al.
Human Vaccines & Immunotherapeutics|June 16, 2012
Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® JuniorRoman Prymula, Eva Maria Pöllabauer, Borislava G Pavlova, et al.
Journal of Virus Eradication|February 26, 2019
Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled studySofie Rutsaert, Jean-Marc Steens, Paul Gineste, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 24, 2012
A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individualsHartmut J Ehrlich, Julia Singer, Gregory Berezuk, et al.
The Journal of Infectious Diseases|November 18, 2011
A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodiesRichard Fritz, Nicolas Sabarth, Stefan Kiermayr, et al.
Seminars in Thrombosis and Hemostasis|July 17, 2010
Structure and function of a recombinant von Willebrand factor drug candidatePeter L Turecek, Gerald Schrenk, Hanspeter Rottensteiner, et al.
Vaccine|December 17, 2011
Clinical development of a Vero cell culture-derived seasonal influenza vaccineHartmut J Ehrlich, Gregory Berezuk, Sandor Fritsch, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Seminars in Thrombosis and Hemostasis|July 16, 2010
Preclinical testing of human recombinant von Willebrand factor: ADAMTS13 cleavage capacity in animals as criterion for species suitabilityEva-Maria Muchitsch, Barbara Dietrich, Hanspeter Rottensteiner, et al.
Antimicrobial Agents and Chemotherapy|November 2, 2016
Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male SubjectsDidier Scherrer, Regine Rouzier, Marine Cardona, et al.
The Journal of Allergy and Clinical Immunology. Global|October 2, 2023
ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trialPedro Giavina-Bianchi, Eric Cua, Karine Risso, et al.
Vaccine|May 11, 2010
Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccineEva Maria Pöllabauer, Sandor Fritsch, Borislava G Pavlova, et al.
Human Vaccines & Immunotherapeutics|June 16, 2012
Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® JuniorRoman Prymula, Eva Maria Pöllabauer, Borislava G Pavlova, et al.
Journal of Virus Eradication|February 26, 2019
Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled studySofie Rutsaert, Jean-Marc Steens, Paul Gineste, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 24, 2012
A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individualsHartmut J Ehrlich, Julia Singer, Gregory Berezuk, et al.
The Journal of Infectious Diseases|November 18, 2011
A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodiesRichard Fritz, Nicolas Sabarth, Stefan Kiermayr, et al.
Seminars in Thrombosis and Hemostasis|July 17, 2010
Structure and function of a recombinant von Willebrand factor drug candidatePeter L Turecek, Gerald Schrenk, Hanspeter Rottensteiner, et al.
Vaccine|December 17, 2011
Clinical development of a Vero cell culture-derived seasonal influenza vaccineHartmut J Ehrlich, Gregory Berezuk, Sandor Fritsch, et al.
Pageof 5